drugset

Drugs / Emapalumab-Izsg

Follow last change Mar 2025 re-read 2 minutes ago

Emapalumab-Izsg

also known as emapalumab

Monoclonal antibody

Developed for: infectious disease with sepsis
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

today NCT05463133 · Ph 1/2

20232024202520262027202820292030203120322033

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT05463133	Jul 2022 → Dec 2032 expected	chronic granulomatous disease	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT06694701 Comparator	Mar 2025 → Nov 2026 expected	infectious disease with sepsis	Hellenic Institute for the Study of Sepsis	Active not recruiting	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Emapalumab-Izsg	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05463133 ↗ 1 NCT06694701 ↗
Known as	emapalumab	“It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFNγ, may improve the outcome of patients with sepsis driven by the IDS (endotype of...” NCT06694701 ↗
Action	Inhibit	“An interferon gamma blocking antibody used to prevent inflammation/engraftment syndrome post HSC transplant.” NCT05463133 ↗
Modality	Monoclonal antibody	“emapalumab, a monoclonal antibody which blocks IFNγ” NCT06694701 ↗